# Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)

> **NCT01605331** · PHASE4 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 132 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** sustained-release recombinant human GH (SR-rhGH)

## Key facts

- **NCT ID:** NCT01605331
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605331, "Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01605331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*